The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of AnaptysBio Inc (NASDAQ: ANAB) closed at $16.51 in the last session, down -1.31% from day before closing price of $16.73. In other words, the price has decreased by -$1.31 from its previous closing price. On the day, 1.09 million shares were traded. ANAB stock price reached its highest trading level at $17.367 during the session, while it also had its lowest trading level at $15.78.
Ratios:
We take a closer look at ANAB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 9.51 and its Current Ratio is at 9.51. In the meantime, Its Debt-to-Equity ratio is 5.21 whereas as Long-Term Debt/Eq ratio is at 5.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wolfe Research on February 04, 2025, initiated with a Outperform rating and assigned the stock a target price of $25.
On December 11, 2024, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $52 to $19.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 30 ’24 when EcoR1 Capital, LLC bought 65,184 shares for $12.92 per share. The transaction valued at 842,060 led to the insider holds 7,860,180 shares of the business.
EcoR1 Capital, LLC bought 13,268 shares of ANAB for $171,513 on Dec 31 ’24. The Director now owns 7,873,448 shares after completing the transaction at $12.93 per share. On Jan 02 ’25, another insider, EcoR1 Capital, LLC, who serves as the Director of the company, bought 6,646 shares for $12.95 each. As a result, the insider paid 86,070 and bolstered with 7,880,094 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ANAB now has a Market Capitalization of 506308864 and an Enterprise Value of 490398560. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.55 while its Price-to-Book (P/B) ratio in mrq is 7.10. Its current Enterprise Value per Revenue stands at 5.372 whereas that against EBITDA is -4.289.
Stock Price History:
The Beta on a monthly basis for ANAB is -0.04, which has changed by -0.2905028 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, ANAB has reached a high of $41.31, while it has fallen to a 52-week low of $12.21. The 50-Day Moving Average of the stock is 0.40%, while the 200-Day Moving Average is calculated to be -35.05%.
Shares Statistics:
According to the various share statistics, ANAB traded on average about 945.65K shares per day over the past 3-months and 762020 shares per day over the past 10 days. A total of 30.47M shares are outstanding, with a floating share count of 28.30M. Insiders hold about 7.73% of the company’s shares, while institutions hold 124.12% stake in the company. Shares short for ANAB as of 1740700800 were 9030127 with a Short Ratio of 9.55, compared to 1738281600 on 6034632. Therefore, it implies a Short% of Shares Outstanding of 9030127 and a Short% of Float of 40.1.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current market rating for AnaptysBio Inc (ANAB) reflects the collective analysis of 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$1.39, with high estimates of -$1.07 and low estimates of -$1.58.
Analysts are recommending an EPS of between -$4.44 and -$6.66 for the fiscal current year, implying an average EPS of -$5.62. EPS for the following year is -$5.73, with 8.0 analysts recommending between -$4.03 and -$6.93.
